Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate,”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“The data generated during the quarter and in recent weeks strengthen the foundation for this next stage and reinforce the opportunity to develop EB-003 as a differentiated treatment for psychiatric and neurological disorders.”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“Recently completed studies of EB-003 have provided important, complementary evidence demonstrating its differentiated profile and potential advantages.”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“Independent assay platforms, including GloSensor™ and BRET, have consistently supported its predicted non-hallucinogenic profile, while our completed in vitro ADMET studies indicate favorable absorption and metabolic properties and a reduced potential for drug-drug interactions.”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“The qEEG study adds functional evidence of brain penetration and a pattern of brain activity distinct from dimethyltryptamine (DMT).”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“It also supports evaluating qEEG in human studies to connect drug exposure with brain activity and help guide dose selection.”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“As the FDA continues to define the regulatory framework for psychedelic-inspired therapies, we believe EB-003’s design has the potential to offer advantages in clinical development while supporting broader patient access and potential commercial adoption,”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“By seeking to harness the therapeutic potential of neuroplasticity without requiring a hallucinogenic experience, our approach could support a simpler outpatient treatment model.”

Joseph Tucker, Chief Executive Officer of Enveric Biosciences

“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”